NCT00951210

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pluristem Ltd. · Industry
• Sex: All
• Age: 40 Years – 81 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety of PLX-PAD, Intra-muscular injections for the treatment of CLI patients.

Conditions

• Peripheral Artery Disease
• Peripheral Vascular Disease
• Critical Limb Ischemia

Interventions

Type	Name	Description
BIOLOGICAL	PLX-PAD	IM injection

Timeline

• Start date: 2009-08-01
• Primary completion: 2011-01-01
• Completion: 2011-10-01
• First posted: 2009-08-04
• Last updated: 2015-05-27

Locations

2 sites across 1 country: United States